The trajectory of copyright's flagship drug presents a interesting case for stakeholders in the pharmaceutical sector. While initially a phenomenal success, creating billions, the exclusivity expiration and the subsequent flood of cheaper competitors have considerably changed income. This presents questions about the long-term sustainability of sim